
Alnylam Pharmaceuticals Inc. scored its third approval from the US Food and Drug Administration in as many years Monday, this time for a medicine to treat a rare disease that affects the kidneys.
The rare disorder — called primary hyperoxaluria type 1 — causes a buildup of oxalate in the body, which when not filtered properly can cause kidney and bladder stones.